MaxCyte (NASDAQ:MXCT - Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.04, Zacks reports. MaxCyte had a negative return on equity of 16.00% and a negative net margin of 78.36%.
MaxCyte Stock Performance
NASDAQ MXCT traded up $0.05 during trading hours on Tuesday, reaching $3.47. The stock had a trading volume of 563,159 shares, compared to its average volume of 592,048. MaxCyte has a 52-week low of $3.16 and a 52-week high of $5.26. The stock has a market cap of $367.68 million, a P/E ratio of -10.21 and a beta of 1.35. The stock has a fifty day moving average of $4.25 and a 200 day moving average of $4.00.
About MaxCyte
(
Get Free Report)
MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider MaxCyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MaxCyte wasn't on the list.
While MaxCyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
